Aripiprazole Lauroxil

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

阿立哌唑月桂酰，阿立哌唑的 N-酰氧基甲基前药形式，是一种长效注射剂 (LAI) 抗精神病药。

Aripiprazole lauroxil, the N-acyloxymethyl prodrug form of aripiprazole, a long-acting injectable (LAI) antipsychotic. Aripiprazole lauroxil is cleaved by esterases in vivo to N-hydroxymethyl aripiprazole (lauric acid), which is then cleaved to aripiprazole, which is non-toxic.(In Vivo):Intravenous administration of 1.87?mg/ml Aripiprazole lauroxil bioconversion in vivo involves the formation of an intermediate,?N-hydroxymethyl aripiprazole. The?in vitro?data indicates a high bioconversion of aripiprazole lauroxil, thus, the concentration of?N-hydroxymethyl aripiprazole observed in the animals dosed with aripiprazole lauroxil is surprisingly high.

——

Animal Model:Female Sprague Dawley ratsDosage:1.87?mg/ml?Administration:Blood samples is taken at 5, 15, 30?min and 1, 2, 4, 6, 8 and 24?h after administration Result:Exhibits an clearance: 0.32?±?0.11?L/h/kg.?

——

GPCR/G Protein

Dopamine Receptor

Mycobacterium tuberculosis

——

——

1259305-29-7

660.72

C36H51Cl2N3O4

>98% (HPLC)

In Vitro:?DMSO : 8.33 mg/mL (12.61 mM)

CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12

——

(-20℃)

With Ice Pack

≥ 2 years